Overview

Hypoxia-guided Radiotherapy With Cisplatin-etoposide in Stage I-III : Small Cell Lung Cancer(SCLC)

Status:
Withdrawn
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
Since radiation dose escalation to a large volume of tumour inevitably will induce higher toxicity than is currently the case, efforts must be made to limit the volume of tissue irradiated. Moreover, the irradiation of larger tumour volumes leads to a lower achievable tumour dose when keeping the normal tissue doses constant. Central is thus the question whether it would be possible to limit the volume of tumour to be boosted by selectively escalating the radiation dose to specific disease sites which are theoretically more prone to relapse.
Phase:
N/A
Details
Lead Sponsor:
Maastricht Radiation Oncology
Collaborator:
Maastricht University Medical Center
Treatments:
Cisplatin
Etoposide